G
Gabriela Burian
Researcher at Novartis
Publications - 8
Citations - 1266
Gabriela Burian is an academic researcher from Novartis. The author has contributed to research in topics: Ranibizumab & Laser coagulation. The author has an hindex of 5, co-authored 8 publications receiving 1123 citations.
Papers
More filters
Journal ArticleDOI
The RESTORE Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema
Paul Mitchell,Francesco Bandello,Ursula Schmidt-Erfurth,Gabriele E. Lang,Pascale Massin,Reinier O. Schlingemann,Florian K. P. Sutter,Christian Simader,Gabriela Burian,Ortrud Gerstner,Andreas Weichselberger +10 more
TL;DR: Ranibizumab monotherapy and combined with laser provided superior visual acuity gain over standard laser in patients with visual impairment due to DME and had a safety profile in DME similar to that in age-related macular degeneration.
Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema
Paul Mitchell,Francesco Bandello,Ursula Schmidt-Erfurth,Gabriele E. Lang,Pascale Massin,Reinier O. Schlingemann,Florian K. P. Sutter,Christian Simader,Gabriela Burian,Ortrud Gerstner,Andreas Weichselberger +10 more
Journal Article
A Phase 2 Study (EMERGE) Evaluating Repeated Intravitreal Administration of ICON-1 in Patients With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Patent
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
Sergey Aksenov,Gabriela Burian +1 more
TL;DR: In this paper, the use of a VEGF antagonist for the treatment of chorioretinal neovascular or permeability disorders in children was discussed, where a method for treating a child having CNV or ME, wherein said method comprises administering to the eye of a child a VegF antagonist that either does not enter or is rapidly cleared from the systemic circulation.
Patent
Use of a vegf antagonist in treating retinopathy of prematurity
Gabriela Burian,Sergey Aksenov +1 more
TL;DR: In this article, the use of a VEGF antagonist in the treatment of retinal neovascular disorders in infants was proposed, where the VEG F antagonist either does not enter or is rapidly cleared from the systemic circulation.